5 results  1 of 1 

1 A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer
Junsik Park, Kyung Jin Eoh, Eun Ji Nam, Sunghoon Kim, Sang Wun Kim, Young Tae Kim, Jung-Yun Lee
Yonsei Med J.2020;61(4):284-290.   Published online 2020 March 25     DOI: http://dx.doi.org/10.3349/ymj.2020.61.4.284
      
2 Negative peritoneal washing cytology during interval debulking surgery predicts overall survival after neoadjuvant chemotherapy for ovarian cancer
Ayaka Iura, Morihito Takita, Aiko Kawano, Kazuaki Imai, Katsuyuki Konnai, Ryo Onose, Hisamori Kato
J Gynecol Oncol.2018;29(5):e70.  Published online 2018 May 4     DOI: http://dx.doi.org/10.3802/jgo.2018.29.e70
      
3 External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma
Jung-Yun Lee, Young Shin Chung, Kiyong Na, Hye Min Kim, Cheol Keun Park, Eun Ji Nam, Sunghoon Kim, Sang Wun Kim, Young Tae Kim, Hyun-Soo Kim
J Gynecol Oncol.2017;28(6):e73.  Published online 2017 July 24     DOI: http://dx.doi.org/10.3802/jgo.2017.28.e73
      
4 CA-125 cut-off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer
Naoto Furukawa, Yoshikazu Sasaki, Aiko Shigemitsu, Juria Akasaka, Seiji Kanayama, Ryuji Kawaguchi, Hiroshi Kobayashi
J Gynecol Oncol.2013;24(2):141-145.   Published online 2013 April 5     DOI: http://dx.doi.org/10.3802/jgo.2013.24.2.141
      
5 Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?
Joseph Menczer, Irena Usviatzov, Erez Ben-Shem, Abraham Golan, Tally Levy
J Gynecol Oncol.2011;22(3):183-187.   Published online 2011 September 28     DOI: http://dx.doi.org/10.3802/jgo.2011.22.3.183
      

 1 of 1